-
October 19, 2022
The turnover from transactions with Bulgarian shares reached just under BGN 6 million, and two-thirds of it (just over BGN 4 million) was formed by transactions with shares of Tchaikapharma High Quality Medicines. Another 4 companies formed another quarter of the turnover, SOFIX recorded a minimal decrease.
Read the full article here in Bulgarian.
-
October 5, 2022
Tchaikapharma has launched two new medicinal products on the market, which are already commercially available:
Methylprednisolone-Chaikapharma (methylprednisolone) 40 mg powder and solvent for for injection solution
TromBai (cilostazol) 100 mg tablets
The distributor of the medicinal products is Commercial League – Global Pharmа Center.
-
July 8, 2022
On July 7, 2022, the Bulgarian Credit Rating Agency (BCRA) has awarded the company with the highest market capitalization on the Bulgarian Stock Exchange Tchaikapharma a long-term credit rating of “BBB-” and a short-term “A” on a national scale. With this, BCRA expresses its opinion that the company maintains a very good financial position with low levels of indebtedness, high creditworthiness, formed satisfactory liquidity, allowing it to timely service its obligations. According to the BCRA’s rating scale, the rating assigned corresponds to an ‘investment grade’ credit rating.
According to the agency’s analysis, the company is a well-established player in the local market with a long-standing (22 years) presence, a well-known name and reputation and an extensive commercial network.
-
July 4, 2022
“Politicians in power have one main task – to create a competitive investment and business environment and deal with the growth of the national economy. The self-esteem of any nation is a product of GDP per capita. Politicians should focus on this issue.” This is what Tihomir Kamenov, a specialist in public and private law, founder of the company group Commercial League, the only Bulgarian senior member of the World Economic Forum in Davos, told BNR.
Read more here.
-
June 13, 2022
Tchaikapharma has expanded its portfolio with another product, namely Fluidoro 10 mg film-coated tablets (with active ingredient prasugrel). It belongs to a group of drugs called platelet antiaggregants – it inhibits the accumulation of platelets and thus reduces the risk of blood clots.
Fluidoro, given concomitantly with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (e.g., unstable angina, non-ST segment elevation myocardial infarction, or ST segment elevation myocardial infarction undergoing primary or delayed percutaneous coronary intervention (PCI).
The medicinal product is available on prescription.
ATC code: B01AC22